GHRP-2 vs Semaglutide
Well Studied vs FDA Approved
monitor Mechanism-based · 47% Both GHRP-2 and Semaglutide affect insulin sensitivity or blood glucose. Monitor fasting glucose and HbA1c. Consider adding an insulin sensitizer (metformin/berberine).
Molecular Data
GHRP-2 Semaglutide
Weight 817.9 Da 4,113.64 Da
Half-life ~30 minutes ~7 days (168 hours)
Chain 6 amino acids 31 amino acids
Type Synthetic hexapeptide GLP-1 receptor agonist
Key Benefits
GHRP-2
01 Potent stimulation of natural growth hormone release
02 Enhanced muscle growth and recovery
03 Improved body composition and fat metabolism
04 Better sleep quality and recovery
05 Increased appetite (can be beneficial for bulking)
06 Maintains natural GH pulsatile release patterns
07 Synergistic effects when combined with GHRH peptides
Semaglutide
01 15-20% average body weight reduction
02 Established cardiovascular protection
03 Convenient once-weekly dosing options
04 Comprehensive safety data from extensive trials
05 Flexible injectable and oral formulations
Dosing Protocols
GHRP-2
100-300 mcg / 2-3x daily
GH optimization 100-150 mcg 2-3x daily
Enhanced results 200-300 mcg 2-3x daily
With GHRH (synergy) 100 mcg each 2-3x daily
Pre-sleep protocol 100-200 mcg Before bed
Semaglutide
0.25mg starting, titrate to 1-2.4mg weekly / Once weekly (same day each week)
Weight Loss Initiation 0.25mg Weekly x 4 weeks, then increase
Weight Loss Maintenance 2.4mg Weekly (after 16-week titration)
Diabetes Management 0.5-1mg Weekly
Cardiovascular Protection 0.5-1mg Weekly
Tolerability-Based 0.25-2.4mg Weekly (individualized)
Side Effects
GHRP-2
Increased appetite (less than GHRP-6)
Mild water retention
Tingling or numbness in extremities
Tiredness or lethargy after injection
Mild headache
Semaglutide
Nausea
Diarrhea
Vomiting
Constipation
Abdominal pain
Contraindications
Active cancer or history of cancer
Pregnancy or breastfeeding
Pituitary disorders
Diabetic retinopathy
WADA prohibited for competitive athletes
Personal or family history of medullary thyroid cancer
Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
Pregnancy or breastfeeding
History of pancreatitis
Research Evidence
GHRP-2 Semaglutide
Status Well Studied FDA Approved
References 3 studies 9 studies
Latest — 2025-06
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.